Email and portals hid trial documents; Part 11 e?sign + validated trial master file with AI search steadied inspections

Overview

Clinical trial compliance records—protocols, amendments, informed consent forms, investigator site files, and approvals—were scattered across email, shared drives, and site portals. Teams rebuilt evidence packets for each inspection, and Part 11 questions about audit trails and e-signatures triggered fire drills. Intelligex implemented validated e-signature workflows, centralized protocol and consent storage in a controlled eTMF with complete audit logs, and permission-aware AI indexing for rapid retrieval. Legal established review gates for critical documents, and study teams answered auditor requests consistently without scrambling—while the existing CTMS, EDC, and IRB portals continued to operate.

Client Profile

• Industry: Biopharma (sponsor running global Phase studies)
• Company size (range): Multi-region sponsor with CRO partners and numerous investigative sites
• Stage: CTMS and EDC in place; trial master file materials split across drives, email, and site portals; mixed use of e-signature; audit readiness inconsistent for 21 CFR Part 11
• Department owner: Legal & Compliance (R&D Compliance and Legal Operations)
• Other stakeholders: Clinical Operations, Quality/QA, Regulatory Affairs, Data Management, IT/Validation, Security/Privacy, CROs, Site Coordinators

The Challenge

Core compliance documents were created and approved in different places. Protocol versions and amendments sat in shared folders, informed consent forms (ICFs) moved through email for signatures, and IRB communications lived on site portals. When inspectors asked for “current protocol and all superseded versions with approval history,” the team pulled files from multiple sources and manually assembled a timeline.

Part 11 controls were inconsistent. Some signatures used a validated process; others were wet-ink or ad hoc electronic approvals without clear audit trails. Identity checks, authority controls, and version management varied by team. During mock inspections, questions about system validation, signature meaning, and record preservation revealed gaps that required rework and declarations.

Search was slow and risky. With materials spread out, staff relied on memory and email to find final ICFs, device accountability logs, or training attestations. Document names and metadata were inconsistent, so producing the right version took time. Legal and QA could not rely on a single source of truth to demonstrate compliance with 21 CFR Part 11 and GCP expectations such as the FDA’s E6 Good Clinical Practice.

Why It Was Happening

The trial master file (TMF) was not consistently centralized. CTMS tracked milestones, and EDC captured clinical data, but many compliance documents stayed in email and shared storage. e-Signature was available but not uniformly configured or validated for Part 11, so teams defaulted to local practices.

Processes weren’t encoded in systems. Document lifecycles, signature routes, and approval authorities were captured in SOPs yet not enforced in the path of work. File metadata varied by author, and audit trails lived in different tools. Without a validated repository and consistent e-sign flow, audit readiness depended on heroic effort before each inspection.

The Solution

Intelligex established a validated repository for protocols, ICFs, and key compliance artifacts, standardized e-signature workflows for Part 11, and added permission-aware AI indexing to speed retrieval. Documents moved through controlled lifecycles with role-based approvals, signatures captured identity and intent under Part 11 controls, and every action wrote to an audit log. AI indexing surfaced the right version quickly while respecting permissions. The design aligned with 21 CFR Part 11, leveraged an eTMF capability (for example, Veeva Vault eTMF), used a life sciences e-signature configuration such as DocuSign for Life Sciences, and mapped to GCP expectations (E6 GCP).

• Integrations: eTMF for controlled storage and audit trails; e-signature with Part 11 controls (identity verification, signature meaning, time-stamps); CTMS for study/site metadata; IRB portal dropboxes for inbound approvals; identity/SSO for roles; collaboration tools for notifications.
• Validated lifecycles: Draft–review–approve–effective workflows for protocols and ICFs; controlled updates with version lineage; authority checks for signers; training attestations tied to effective versions.
• Part 11 controls: System validation documentation (IQ/OQ/PQ), secure user accounts, authority and device controls, closed-system audit trails, signature manifestation on records, and retention aligned to policy.
• AI indexing and search: Permission-aware indexing of final and superseded versions; extraction of key fields (study, site, IRB, effective date, language); quick answers to “current ICF for Site X” with links to evidence; human-in-the-loop curation for high-impact document types.
• Legal/QA oversight: Review gates for critical items (protocols, ICFs, investigator brochures, safety letters); deviation reason codes; change control records for version updates.
• Dashboards and evidence: Completeness of TMF sections; document currency by study/site; signature and approval status; audit export packets with version history, signatures, and logs.
• Security and privacy: Role-based access; minimal PHI in notifications; immutable logs; encryption in transit/at rest; retention and legal hold aligned to policy and regulatory expectations.

Implementation

• Discovery: Mapped document flows for protocols, ICFs, IRB approvals, and training; inventoried existing repositories and signature methods; assessed SOPs against Part 11 controls; sampled inspector requests and prior findings; gathered Legal, QA, Clinical Ops, and IT/Validation requirements.
• Design: Authored document lifecycles and approval routes; defined signer roles and signature meaning; specified Part 11 control set and validation approach (IQ/OQ/PQ); planned CTMS/eTMF mappings and IRB ingestion; designed AI indexing targets and permission trims; outlined dashboards and audit export formats; set change control for templates and workflows.
• Build: Configured the eTMF with controlled content types and metadata; implemented Part 11 e-signature templates and routing; set up IRB portal ingest and CTMS synchronization; executed validation (test scripts, traceability, summary report); enabled AI indexing and permission-aware search; instrumented logs, SSO, and dashboards.
• Testing/QA: Performed end-to-end validation (OQ/PQ) of e-sign flows, audit trails, and locked records; tested lifecycle gating and authority checks; verified IRB/CTMS mappings; ran search scenarios for common inspector asks; piloted with active studies; tuned metadata, templates, and search facets with QA feedback.
• Rollout: Onboarded live studies in waves; migrated finalized documents first, then active drafts; enabled e-signature for protocols and ICFs, followed by broader document classes; retained legacy repositories read-only as a fallback during transition; tightened access and template locks after stable cycles.
• Training/hand-off: Delivered training for study teams and sites on e-sign and lifecycles; briefed Legal/QA on review gates and audit exports; trained IT/Validation on change control and periodic review; updated SOPs and work instructions; transferred ownership of templates, control sets, and dashboards to R&D Compliance and QA under change control.
• Human-in-the-loop review: Established a review board to assess deviation requests, AI indexing misses, and change proposals; recorded decisions with rationale and effective dates; updated templates, metadata, and search curation accordingly.

Results

Documents moved through validated workflows and landed in one audited repository. Protocols and ICFs carried clear version lineage, signatures captured intent and authority, and search returned the right document for the right site with confidence. When auditors requested current and prior versions with approval history, teams exported evidence packets instead of crafting them from email.

Audit readiness steadied. Legal and QA had review gates for critical items, CTMS context enriched metadata, and AI indexing reduced time spent hunting for files while respecting permissions. Inspector questions about Part 11 controls were answered with validation packages, audit logs, and signature manifests. Existing CTMS, EDC, and IRB processes remained; the change added validated e-sign, centralized storage, and governed retrieval between them.

What Changed for the Team

• Before: Protocols and ICFs lived in email and shared drives. After: A validated eTMF held controlled versions with audit trails.
• Before: Mixed signature practices. After: Part 11–compliant e-sign routing captured identity, authority, and intent.
• Before: Scramble to assemble inspector packets. After: One-click exports with version history, signatures, and logs.
• Before: Uncertain “current” documents by site. After: Permission-aware search answered “current vs. superseded” reliably.
• Before: SOPs not enforced in tools. After: Lifecycles, review gates, and change control lived in the workflow.
• Before: Manual cross-checks with CTMS/IRB. After: Mappings and ingestion kept metadata aligned and complete.

Key Takeaways

• Validate the path of work; Part 11 controls must be embedded in e-sign and document lifecycles, not just in SOPs.
• Centralize the TMF; one audited repository beats stitching together email, drives, and portals.
• Make search permission-aware; fast retrieval matters only if it returns the right version to the right person.
• Keep Legal/QA in the loop; review gates for critical documents reduce rework and inspection risk.
• Integrate, don’t replace; keep CTMS, EDC, and IRB—add validated e-sign, metadata mapping, and audit-ready storage between them.
• Prove it; maintain validation artifacts (IQ/OQ/PQ), audit trails, and signature manifests for consistent inspector responses.

FAQ

What tools did this integrate with? A validated eTMF served as the controlled repository (for example, Veeva Vault eTMF), e-signature used a Part 11 configuration such as DocuSign for Life Sciences, and CTMS provided study/site context. IRB portal outputs were ingested to keep approvals aligned. Controls and validation mapped to 21 CFR Part 11 and E6 GCP.

How did you handle quality control and governance? Document lifecycles, signer roles, and templates lived under change control. The system was validated with IQ/OQ/PQ and maintained with periodic reviews. Legal/QA approvals were required for protocols, ICFs, and other critical artifacts. Every view, edit, signature, and version change wrote to an immutable audit trail.

How did you roll this out without disruption? We migrated finalized documents first and ran new workflows in parallel with legacy processes. e-Signature launched for protocols and ICFs before expanding. Legacy repositories remained read-only during transition, and site communications continued via existing portals with automated ingestion into the eTMF.

How did you ensure Part 11 compliance for e-signatures? The e-sign solution enforced unique user IDs, authority checks, signature meaning, secure time-stamps, and audit trails. Validation demonstrated intended use (IQ/OQ/PQ), and signature manifestation appeared on records. Access used SSO with role-based controls, and training attested users’ understanding of signature meaning.

What about AI indexing and privacy? Indexing respected the same permissions as the eTMF, returning only documents a user is authorized to see. Extracted metadata was limited to compliance fields (study, site, version, effective date). AI operated under guardrails with human curation for high-impact documents, and logs captured queries and results for quality review.

How did this handle translations and site-specific ICFs? Site and language variants used the same lifecycle with localized metadata. Search facets filtered by site and language, and the repository tracked which version was effective at each site with IRB approvals linked.

Can this support CRO partners and external auditors? Yes. External users received scoped access with role-based permissions, and audit exports provided self-contained packets when read-only access wasn’t appropriate.

What evidence did you provide to inspectors? Validation plans and reports, audit logs for document lifecycles and signatures, version histories with supersedence, and exports showing the current document, prior versions, approval routes, and signature manifests.